Glucocorticoids as Predictors of Treatment Response in Depression

REFERENCES

• De Kloet ER. Hormones and the stressed brain. Ann N Y Acad Sci 2004;1018:1–15.
   PubMed Web of Science ®Google Scholar
• Holsboer F, Ising M. Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol;61:81–109, C1–11.
   PubMedGoogle Scholar
• Herman JP, Cullinan WE. Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci 1997;20:78–84.
   PubMed Web of Science ®Google Scholar
• Reul JM, de Kloet ER. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 1985;117:2505–11.
   PubMed Web of Science ®Google Scholar
• De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998;19:269–301.
   PubMed Web of Science ®Google Scholar
• Herman JP, Figueiredo H, Mueller NK, Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front Neuroendocrinol 2003;24:151–80.
   PubMed Web of Science ®Google Scholar
• Trapp T, Rupprecht R, Castren M, Reul JM, Holsboer F. Heterodimerization between mineralocorticoid and glucocorticoid receptor: a new principle of glucocorticoid action in the CNS. Neuron 1994;13:1457–62.
   PubMed Web of Science ®Google Scholar
• Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 1997;18:306–60.
   PubMed Web of Science ®Google Scholar
• Pratt WB, Morishima Y, Murphy M, Harrell M. Chaperoning of glucocorticoid receptors. Handb Exp Pharmacol 2006;(172):111–38.
   Google Scholar
• Echeverria PC, Picard D. Molecular chaperones, essential partners of steroid hormone receptors for activity and mobility. Biochim Biophys Acta 2010;1803:641–9.
   PubMed Web of Science ®Google Scholar
• Muller MB, Keck ME, Binder EB, ABCB1 (MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary-adrenocortical system: implications for affective disorder. Neuropsychopharmacology 2003;28:1991–9.
   PubMed Web of Science ®Google Scholar
• Uhr M, Holsboer F, Muller MB. Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J Neuroendocrinol 2002;14:753–9.
   PubMed Web of Science ®Google Scholar
• Uhr M, Tontsch A, Namendorf C, Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008;57:203–9.
   PubMed Web of Science ®Google Scholar
• McEwen BS. Mood disorders and allostatic load. Biol Psychiatry 2003;54:200–7.
   PubMed Web of Science ®Google Scholar
• Heim C, Nemeroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry 2001;49:1023–39.
   PubMed Web of Science ®Google Scholar
• Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000;23:477–501.
   PubMed Web of Science ®Google Scholar
• de Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci 2005;6:463–75.
   PubMed Web of Science ®Google Scholar
• Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003;160:1554–65.
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Widerlov E, Bissette G, Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984;226:1342–4.
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 1988;45:577–9.
   PubMed Web of Science ®Google Scholar
• Merali Z, Du L, Hrdina P, Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci 2004;24:1478–85.
   PubMed Web of Science ®Google Scholar
• Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994;60:436–44.
   PubMed Web of Science ®Google Scholar
• Purba JS, Hoogendijk WJ, Hofman MA, Swaab DF. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 1996;53:137–43.
   PubMed Web of Science ®Google Scholar
• Linkowski P, Mendlewicz J, Leclercq R, The 24-hour profile of adrenocorticotropin and cortisol in major depressive illness. J Clin Endocrinol Metab 1985;61:429–38.
   PubMed Web of Science ®Google Scholar
• Mortola JF, Liu JH, Gillin JC, Rasmussen DD, Yen SS. Pulsatile rhythms of adrenocorticotropin (ACTH) and cortisol in women with endogenous depression: evidence for increased ACTH pulse frequency. J Clin Endocrinol Metab 1987;65:962–8.
   PubMedGoogle Scholar
• Rubin RT, Poland RE, Lesser IM, Winston RA, Blodgett AL. Neuroendocrine aspects of primary endogenous depression. I. Cortisol secretory dynamics in patients and matched controls. Arch Gen Psychiatry 1987;44:328–36.
   PubMed Web of Science ®Google Scholar
• Green HS, Kane JM. The dexamethasone suppression test in depression. Clin Neuropharmacol 1983;6:7–24.
   PubMedGoogle Scholar
• Nemeroff CB, Krishnan KR, Reed D, Leder R, Beam C, Dunnick NR. Adrenal gland enlargement in major depression. A computed tomographic study. Arch Gen Psychiatry 1992;49:384–7.
   PubMed Web of Science ®Google Scholar
• Axelson DA, Doraiswamy PM, Boyko OB, In vivo assessment of pituitary volume with magnetic resonance imaging and systematic stereology: relationship to dexamethasone suppression test results in patients. Psychiatry Res 1992;44:63–70.
   PubMed Web of Science ®Google Scholar
• Holsboer F, Liebl R, Hofschuster E. Repeated dexamethasone suppression test during depressive illness. Normalisation of test result compared with clinical improvement. J Affect Disord 1982;4:93–101.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Davis JM. DST studies in psychotic depression: a meta-analysis. Am J Psychiatry 1997;154:1497–503.
   PubMed Web of Science ®Google Scholar
• Arana GW, Wilens TE, Baldessarini RJ. Plasma corticosterone and cortisol following dexamethasone in psychiatric patients. Psychoneuroendocrinology 1985;10:49–60.
   PubMedGoogle Scholar
• Holsboer F, Von Bardeleben U, Gerken A, Stalla GK, Muller OA. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N Engl J Med 1984;311:1127.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Maislin G, Winokur A, Berwish N, Kling M, Gold P. The oCRH stimulation test before and after clinical recovery from depression. J Affect Disord 1988;14:213–22.
   PubMedGoogle Scholar
• Gold PW, Chrousos G, Kellner C, Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am J Psychiatry 1984;141:619–27.
   PubMed Web of Science ®Google Scholar
• Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 1994;28:341–56.
   PubMed Web of Science ®Google Scholar
• Holsboer F, von Bardeleben U, Wiedemann K, Muller OA, Stalla GK. Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression. Biol Psychiatry 1987;22:228–34.
   PubMedGoogle Scholar
• Ising M, Kunzel HE, Binder EB, Nickel T, Modell S, Holsboer F. The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1085–93.
   PubMed Web of Science ®Google Scholar
• Watson S, Gallagher P, Smith MS, Ferrier IN, Young AH. The dex/CRH test—is it better than the DST? Psychoneuroendocrinology 2006;31:889–94.
   PubMed Web of Science ®Google Scholar
• Carpenter LL, Ross NS, Tyrka AR, Anderson GM, Kelly M, Price LH. Dex/CRH test cortisol response in outpatients with major depression and matched healthy controls. Psychoneuroendocrinology 2009.
   PubMedGoogle Scholar
• Heim C, Mletzko T, Purselle D, Musselman DL, Nemeroff CB. The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma. Biol Psychiatry 2008;63:398–405.
   PubMed Web of Science ®Google Scholar
• Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 1996;17:187–205.
   PubMed Web of Science ®Google Scholar
• Keck ME, Holsboer F. Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides 2001;22:835–44.
   PubMed Web of Science ®Google Scholar
• von Bardeleben U, Holsboer F, Stalla GK, Muller OA. Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci 1985;37:1613–8.
   PubMed Web of Science ®Google Scholar
• Kunzel HE, Binder EB, Nickel T, Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test. Neuropsychopharmacology 2003;28:2169–78.
   PubMed Web of Science ®Google Scholar
• Oshima A, Miyano H, Yamashita S, Psychological, autonomic and neuroendocrine responses to acute stressors in the combined dexamethasone/CRH test: a study in healthy subjects. J Psychiatr Res 2001;35:95–104.
   PubMedGoogle Scholar
• Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. A prospective study. J Psychiatr Res 2001;35:83–94.
   PubMed Web of Science ®Google Scholar
• von Bardeleben U, Wiedemann K, Stalla GK, Muller OA, Holsboer F. Exaggerated corticotrophic cell response to human corticotropin-releasing hormone in two patients during long-term carbamazepine treatment. Biol Psychiatry 1988;24:331–5.
   PubMedGoogle Scholar
• Bschor T, Baethge C, Adli M, Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression. Depress Anxiety 2003;17:43–8.
   PubMedGoogle Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2:347–56.
   PubMed Web of Science ®Google Scholar
• Keitner GI, Fruzzetti AE, Miller IW, Norman WH, Brown WA. The effect of anticonvulsants on the dexamethasone suppression test. Can J Psychiatry 1989;34:441–3.
   PubMedGoogle Scholar
• Rybakowski JK, Twardowska K. The dexamethasone/ corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. J Psychiatr Res 1999;33:363–70.
   PubMed Web of Science ®Google Scholar
• Erhardt A, Ising M, Unschuld PG, Regulation of the hypothalamic-pituitary-adrenocortical system in patients with panic disorder. Neuropsychopharmacology 2006;31:2515–22.
   PubMed Web of Science ®Google Scholar
• Schreiber W, Lauer CJ, Krumrey K, Holsboer F, Krieg JC. Dysregulation of the hypothalamic-pituitary-adrenocortical system in panic disorder. Neuropsychopharmacology 1996;15:7–15.
   PubMedGoogle Scholar
• Schmider J, Lammers CH, Gotthardt U, Dettling M, Holsboer F, Heuser IJ. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol Psychiatry 1995;38:797–802.
   PubMed Web of Science ®Google Scholar
• Lammers CH, Garcia-Borreguero D, Schmider J, Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biol Psychiatry 1995;38:803–7.
   PubMed Web of Science ®Google Scholar
• Then Bergh F, Kumpfel T, Grasser A, Rupprecht R, Holsboer F, Trenkwalder C. Combined treatment with corticosteroids and moclobemide favors normalization of hypothalamo-pituitary-adrenal axis dysregulation in relapsing-remitting multiple sclerosis: a randomized, double blind trial. J Clin Endocrinol Metab 2001;86:1610–5.
   PubMedGoogle Scholar
• Arana GW, Baldessarini RJ, Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Commentary and review. Arch Gen Psychiatry 1985;42:1193–204.
   PubMed Web of Science ®Google Scholar
• Heuser IJ, Gotthardt U, Schweiger U, Age-associated changes of pituitary-adrenocortical hormone regulation in humans: importance of gender. Neurobiol Aging 1994;15: 227–31.
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Owens MJ. Treatment of mood disorders. Nat Neurosci 2002;5 suppl:1068–70.
   PubMedGoogle Scholar
• Reul JM, Stec I, Soder M, Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 1993;133:312–20.
   PubMed Web of Science ®Google Scholar
• Reul JM, Labeur MS, Grigoriadis DE, De Souza EB, Holsboer F. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 1994;60:509–19.
   PubMed Web of Science ®Google Scholar
• Nemeroff CB. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol Psychiatry 1996;1:336–42.
   PubMed Web of Science ®Google Scholar
• Greden JF, Gardner R, King D, Grunhaus L, Carroll BJ, Kronfol Z. Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility. Arch Gen Psychiatry 1983;40:493–500.
   PubMed Web of Science ®Google Scholar
• Ribeiro SC, Tandon R, Grunhaus L, Greden JF. The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry 1993;150:1618–29.
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Evans DL. Correlation between the dexamethasone suppression test in depressed patients and clinical response. Am J Psychiatry 1984;141:247–9.
   PubMedGoogle Scholar
• Deuschle M, Schweiger U, Weber B, Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab 1997;82:234–8.
   PubMed Web of Science ®Google Scholar
• Frieboes RM, Sonntag A, Yassouridis A, Eap CB, Baumann P, Steiger A. Clinical outcome after trimipramine in patients with delusional depression—a pilot study. Pharmacopsychiatry 2003;36:12–7.
   PubMed Web of Science ®Google Scholar
• Heuser IJ, Schweiger U, Gotthardt U, Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry 1996;153:93–9.
   PubMed Web of Science ®Google Scholar
• Holsboer-Trachsler E, Stohler R, Hatzinger M. Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. Psychiatry Res 1991;38:163–71.
   PubMedGoogle Scholar
• Holsboer-Trachsler E, Hemmeter U, Hatzinger M, Seifritz E, Gerhard U, Hobi V. Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment—neurobiological and psychometric assessment of course. J Psychiatr Res 1994;28:381–99.
   PubMed Web of Science ®Google Scholar
• Nickel T, Sonntag A, Schill J, Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol 2003;23:155–68.
   PubMed Web of Science ®Google Scholar
• Rinne T, de Kloet ER, Wouters L, Goekoop JG, de Rijk RH, Van Den Brink W. Fluvoxamine reduces responsiveness of HPA axis in adult female BPD patients with a history of sustained childhood abuse. Neuropsychopharmacology 2003;28: 126–32.
   PubMedGoogle Scholar
• Schule C, Baghai TC, Eser D, Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients. Psychopharmacology (Berl) 2006;186:601–11.
   PubMed Web of Science ®Google Scholar
• Schule C, Baghai T, Zwanzger P, Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine. Psychopharmacology (Berl) 2003;166:271–5.
   PubMed Web of Science ®Google Scholar
• Horstmann S, Dose T, Lucae S, Suppressive effect of mirtazapine on the HPA system in acutely depressed women seems to be transient and not related to antidepressant action. Psychoneuroendocrinology 2009;34:238–48.
   PubMedGoogle Scholar
• Kunugi H, Ida I, Owashi T, Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a multicenter study. Neuropsychopharmacology 2006;31:212–20.
   PubMed Web of Science ®Google Scholar
• Yuuki N, Ida I, Oshima A, HPA axis normalization, estimated by DEX/CRH test, but less alteration on cerebral glucose metabolism in depressed patients receiving ECT after medication treatment failures. Acta Psychiatr Scand 2005;112:257–65.
   PubMed Web of Science ®Google Scholar
• Albala AA, Greden JF, Tarika J, Carroll BJ. Changes in serial dexamethasone suppression tests among unipolar depressive receiving electroconvulsive treatment. Biol Psychiatry 1981;16:551–60.
   PubMedGoogle Scholar
• Zwanzger P, Baghai TC, Padberg F, The combined dexamethasone-CRH test before and after repetitive transcranial magnetic stimulation (rTMS) in major depression. Psychoneuroendocrinology 2003;28:376–85.
   PubMed Web of Science ®Google Scholar
• Hennings JM, Owashi T, Binder EB, Clinical characteristics and treatment outcome in a representative sample of depressed inpatients—findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009;43:215–29.
   PubMed Web of Science ®Google Scholar
• Laakmann G, Hennig J, Baghai T, Schule C. Influence of mirtazapine on salivary cortisol in depressed patients. Neuropsychobiology 2003;47:31–6.
   PubMedGoogle Scholar
• Binder EB, Kunzel HE, Nickel T, HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients. Psychoneuroendocrinology 2009;34:99–109.
   PubMed Web of Science ®Google Scholar
• Deuschle M, Schmider J, Weber B, Pulse-dosing and conventional application of doxepin: effects on psychopathology and hypothalamus-pituitary-adrenal (HPA) system. J Clin Psychopharmacol 1997;17:156–60.
   PubMedGoogle Scholar
• Hatzinger M, Hemmeter UM, Baumann K, Brand S, Holsboer-Trachsler E. The combined DEX-CRH test in treatment course and long-term outcome of major depression. J Psychiatr Res 2002;36:287–97.
   PubMed Web of Science ®Google Scholar
• Bschor T, Baethge C, Adli M, Association between response to lithium augmentation and the combined DEX/CRH test in major depressive disorder. J Psychiatr Res 2003;37:135–43.
   PubMedGoogle Scholar
• Nikisch G, Mathe AA, Czernik A, Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology (Berl) 2005;181:751–60.
   PubMedGoogle Scholar
• Appelhof BC, Huyser J, Verweij M, Glucocorticoids and relapse of major depression (dexamethasone/corticotropin-releasing hormone test in relation to relapse of major depression). Biol Psychiatry 2005.
   PubMedGoogle Scholar
• Ising M, Horstmann S, Kloiber S, Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression—a potential biomarker? Biol Psychiatry 2007;62:47–54.
   PubMed Web of Science ®Google Scholar
• Aubry JM, Gervasoni N, Osiek C, The dex/CRH neuroendocrine test and the prediction of depressive relapse in remitted depressed outpatients. J Psychiatr Res 2007;41:290–4.
   PubMed Web of Science ®Google Scholar
• Himmerich H, Binder EB, Kunzel HE, Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol Psychiatry 2006;60:882–8.
   PubMed Web of Science ®Google Scholar
• Paslakis G, Heuser I, Schweiger U, Deuschle M. A single dex/CRH test in male drug-free depressed patients is associated with the clinical response to treatment with fluoxetine. J Psychiatr Res 2010;44:1154–7.
   PubMedGoogle Scholar
• Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry;71 suppl E1:e04.
   Google Scholar
• Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179–200.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28–40.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231–42.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Fava M, Wisniewski SR, Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243–52.
   PubMed Web of Science ®Google Scholar
• Fava M, Rush AJ, Wisniewski SR, A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006;163:1161–72.
   PubMed Web of Science ®Google Scholar
• Zobel AW, Yassouridis A, Frieboes RM, Holsboer F. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry 1999;156:949–51.
   PubMed Web of Science ®Google Scholar
• Appelhof BC, Huyser J, Verweij M, Glucocorticoids and relapse of major depression (dexamethasone/corticotropin-releasing hormone test in relation to relapse of major depression). Biol Psychiatry 2006;59:696–701.
   PubMed Web of Science ®Google Scholar
• Heim C, Newport DJ, Mletzko T, Miller AH, Nemeroff CB. The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology 2008;33:693–710.
   PubMed Web of Science ®Google Scholar
• Tyrka AR, Wier L, Price LH, Childhood parental loss and adult hypothalamic-pituitary-adrenal function. Biol Psychiatry 2008;63:1147–54.
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Heim CM, Thase ME, Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA 2003;100:14293–6.
   PubMed Web of Science ®Google Scholar
• Bradley RG, Binder EB, Epstein MP, Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry 2008;65:190–200.
   PubMed Web of Science ®Google Scholar
• Polanczyk G, Caspi A, Williams B, Protective effect of CRHR1 gene variants on the development of adult depression following childhood maltreatment: replication and extension. Arch Gen Psychiatry 2009;66:978–85.
   PubMed Web of Science ®Google Scholar
• Ressler KJ, Bradley B, Mercer KB, Polymorphisms in CRHR1 and the serotonin transporter loci: gene x gene x environment interactions on depressive symptoms. American Journal of Medical Genetics, Part B Psychiatric Genetics 2009; Dec 22. [Epub ahead of print].
   Google Scholar
• Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry;167:509–27.
   PubMed Web of Science ®Google Scholar
• Tyrka AR, Price LH, Gelernter J, Schepker C, Anderson GM, Carpenter LL. Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis reactivity. Biol Psychiatry 2009;66:681–5.
   PubMed Web of Science ®Google Scholar
• Heim C, Bradley B, Mletzko TC, Effect of childhood trauma on adult depression and neuroendocrine function: sex-specific moderation by CRG receptor 1 gene. Front Behav Neurosci 2009;3:41.
   PubMedGoogle Scholar
• Alexander N, Kuepper Y, Schmitz A, Osinsky R, Kozyra E, Hennig J. Gene-environment interactions predict cortisol responses after acute stress: implications for the etiology of depression. Psychoneuroendocrinology 2009;34:1294–303.
   PubMed Web of Science ®Google Scholar
• Coplan JD, Abdallah CG, Kaufman J, Early-life stress, corticotropin-releasing factor, and serotonin transporter gene: a pilot study. Psychoneuroendocrinology 2010.
   PubMedGoogle Scholar
• Barr CS, Newman TK, Shannon C, Rearing condition and rh5-HTTLPR interact to influence limbic-hypothalamic-pituitary-adrenal axis response to stress in infant macaques. Biol Psychiatry 2004;55:733–8.
   PubMed Web of Science ®Google Scholar
• McCormack K, Newman TK, Higley JD, Maestripieri D, Sanchez MM. Serotonin transporter gene variation, infant abuse, and responsiveness to stress in rhesus macaque mothers and infants. Horm Behav 2009;55:538–47.
   PubMed Web of Science ®Google Scholar
• Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 2008;165:617–20.
   PubMed Web of Science ®Google Scholar
• Ising M, Zimmermann US, Kunzel HE, High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology 2007;32:1941–9.
   PubMed Web of Science ®Google Scholar
• Kimura M, Muller-Preuss P, Lu A, Conditional corticotropin-releasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleep. Mol Psychiatry 2009.
   PubMedGoogle Scholar
• Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 2001;21:516–21.
   PubMed Web of Science ®Google Scholar
• Belanoff JK, Rothschild AJ, Cassidy F, An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002;52:386–92.
   PubMed Web of Science ®Google Scholar
• Simpson GM, El Sheshai A, Loza N, An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. J Clin Psychiatry 2005;66: 598–602.
   PubMed Web of Science ®Google Scholar
• DeBattista C, Belanoff J, Glass S, Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry 2006;60:1343–9.
   PubMed Web of Science ®Google Scholar
• Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 2006;31:628–36.
   PubMed Web of Science ®Google Scholar
• Blasey CM, Debattista C, Roe R, Block T, Belanoff JK. A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction. Contemp Clin Trials 2009;30:284–8.
   PubMed Web of Science ®Google Scholar
• Rothschild AJ, Schatzberg AF, Langlais PJ, Lerbinger JE, Miller MM, Cole JO. Psychotic and nonpsychotic depressions: I. Comparison of plasma catecholamines and cortisol measures. Psychiatry Res 1987;20:143–53.
   PubMed Web of Science ®Google Scholar
• Schatzberg AF, Rothschild AJ. The roles of glucocorticoid and dopaminergic systems in delusional (psychotic) depression. Ann N Y Acad Sci 1988;537:462–71.
   PubMed Web of Science ®Google Scholar
• Posener JA, DeBattista C, Williams GH, Chmura Kraemer H, Kalehzan BM, Schatzberg AF. 24-hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch Gen Psychiatry 2000;57:755–60.
   PubMed Web of Science ®Google Scholar
• Keller J, Flores B, Gomez RG, Cortisol circadian rhythm alterations in psychotic major depression. Biol Psychiatry 2006;60:275–81.
   PubMed Web of Science ®Google Scholar
• Binder EB, Salyakina D, Lichtner P, Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004;36:1319–25.
   PubMed Web of Science ®Google Scholar
• Binder EB, Owens MJ, Liu W, Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry 2010;67:369–79.
   PubMed Web of Science ®Google Scholar
• Papiol S, Arias B, Gasto C, Gutierrez B, Catalan R, Fananas L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord 2007;104:83–90.
   PubMed Web of Science ®Google Scholar
• Licinio J, O'Kirwan F, Irizarry K, Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry 2004;9:1075–82.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhu F, Wang G, Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett 2007;414:155–8.
   PubMed Web of Science ®Google Scholar
• Uher R, Perroud N, Ng MY, Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010;167:555–64.
   PubMed Web of Science ®Google Scholar
• van Rossum EF, Binder EB, Majer M, Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry 2006;59:681–8.
   PubMed Web of Science ®Google Scholar
• Brouwer JP, Appelhof BC, van Rossum EF, Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. Psychoneuroendocrinology 2006;31:1154–63.
   PubMed Web of Science ®Google Scholar
• Uher R, Huezo-Diaz P, Perroud N, Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 2009;9:225–33.
   PubMed Web of Science ®Google Scholar
• Lekman M, Laje G, Charney D, The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) cohort. Biol Psychiatry 2008.
   PubMedGoogle Scholar
• Kirchheiner J, Lorch R, Lebedeva E, Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 2008;9:841–6.
   PubMed Web of Science ®Google Scholar
• Tsai SJ, Hong CJ, Chen TJ, Yu YW. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am J Med Genet B Neuropsychiatr Genet 2007;144:1097–8.
   Google Scholar
• Perlis RH, Fijal B, Adams DH, Sutton VK, Trivedi MH, Houston JP. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry 2009;65:785–91.
   PubMed Web of Science ®Google Scholar
• DeRijk RH, Schaaf M, de Kloet ER. Glucocorticoid receptor variants: clinical implications. J Steroid Biochem Mol Biol 2002;81:103–22.
   PubMed Web of Science ®Google Scholar
• Derijk RH, van Leeuwen N, Klok MD, Zitman FG. Corticosteroid receptor-gene variants: modulators of the stress-response and implications for mental health. Eur J Pharmacol 2008;585:492–501.
   PubMedGoogle Scholar
• van Rossum EF, Koper JW, Huizenga NA, A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes 2002;51: 3128–34.
   PubMed Web of Science ®Google Scholar
• van West D, Van Den Eede F, Del-Favero J, Glucocorticoid receptor gene-based SNP analysis in patients with recurrent major depression. Neuropsychopharmacology 2006;31:620–7.
   PubMedGoogle Scholar
• Bet PM, Penninx BW, Bochdanovits Z, Glucocorticoid receptor gene polymorphisms and childhood adversity are associated with depression: new evidence for a gene-environment interaction. Am J Med Genet B Neuropsychiatr Genet 2009;150B:660–9.
   PubMedGoogle Scholar
• Garriock HA, Kraft JB, Shyn SI, A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010;67:133–8.
   PubMed Web of Science ®Google Scholar
• Ising M, Lucae S, Binder E, A genome-wide association study points to multiple loci predicting treatment outcome in depression. Arch Gen Psychiatry 2009;66:966–75.
   PubMed Web of Science ®Google Scholar
• Schiene-Fischer C, Yu C. Receptor accessory folding helper enzymes: the functional role of peptidyl prolyl cis/trans isomerases. FEBS Lett 2001;495:1–6.
   PubMed Web of Science ®Google Scholar
• Davies TH, Ning YM, Sanchez ER. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry 2005;44:2030–8.
   PubMed Web of Science ®Google Scholar
• Perlis RH, Fijal B, Adams DH, Sutton VK, Trivedi MH, Houston JP. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry 2009;65:785–91.
   PubMed Web of Science ®Google Scholar
• Zobel A, Schuhmacher A, Jessen F, DNA sequence variants of the FKBP5 gene are associated with unipolar depression. Int J Neuropsychopharmacol;13:649–60.
   PubMedGoogle Scholar
• Sarginson JE, Lazzeroni LC, Ryan HS, Schatzberg AF, Murphy GM, Jr. FKBP5 polymorphisms and antidepressant response in geriatric depression. Am J Med Genet B Neuropsychiatr Genet;153B:554–60.
   PubMedGoogle Scholar
• Zou YF, Wang F, Feng XL, Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neurosci Lett;484:56–61.
   PubMedGoogle Scholar
• Binder EB, Bradley RG, Liu W, Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 2008;299:1–15.
   Google Scholar
• Willour VL, Chen H, Toolan J, Family-based association of FKBP5 in bipolar disorder. Mol Psychiatry 2008.
   PubMedGoogle Scholar
• Xie P, Kranzler HR, Poling J, Interaction of FKBP5 with childhood adversity on risk for post-traumatic stress disorder. Neuropsychopharmacology;35:1684–92.
   PubMedGoogle Scholar
• Ising M, Depping AM, Siebertz A, Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur J Neurosci 2008;28:389–98.
   PubMed Web of Science ®Google Scholar
• Binder EB, Nemeroff CB. The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol Psychiatry 2010;15:574–88.
   PubMed Web of Science ®Google Scholar
• Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry 2009;14: 1105–18.
   PubMed Web of Science ®Google Scholar
• Horstmann S, Lucae S, Menke A, Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 2009; Nov 18 [Epub ahead of print].
   PubMedGoogle Scholar
• Binder EB, Owens MJ, Liu W, Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry 2010;67:369–79.
   PubMed Web of Science ®Google Scholar
• Keers R, Uher R, Huezo-Diaz P, Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics J.
   Google Scholar
• Holsboer F. How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci 2008;9:638–46.
   PubMed Web of Science ®Google Scholar
• Menke A, Puetz B, Weber P, Genome-wide gene-expression profiles following glucocorticoid stimulation associated with major depression. Biol Psychiatry 2010;67:454.
   Google Scholar
• Yehuda R, Golier JA, Yang RK, Tischler L. Enhanced sensitivity to glucocorticoids in peripheral mononuclear leukocytes in posttraumatic stress disorder. Biol Psychiatry 2004;55:1110–6.
   PubMed Web of Science ®Google Scholar
• von Kanel R, Schmid JP, Abbas CC, Gander ML, Saner H, Begre S. Stress hormones in patients with posttraumatic stress disorder caused by myocardial infarction and role of comorbid depression. J Affect Disord 2009;121:73–9.
   PubMedGoogle Scholar